Tissue-agnostic RET inhibition: can you trust your target?
- PMID: 36108663
- DOI: 10.1016/S1470-2045(22)00556-3
Tissue-agnostic RET inhibition: can you trust your target?
Conflict of interest statement
BH reports research funding from Boehringer Ingelheim, AstraZeneca, Merck, Bristol Myers Squibb, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GlaxoSmithKline, Beigene, and Janssen (to BH's institution), and consulting fees from AstraZeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, Bristol Myers Squibb, Genentech, Pfizer, TPT, Arcus, and Veracyte (to BH). AD’A declares no competing interests.
Comment on
-
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: 10.1016/S1470-2045(22)00541-1. Epub 2022 Sep 12. Lancet Oncol. 2022. PMID: 36108661 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources